Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31054229 | 0.81 | PPARA (0.58) | NPC1RAB9AGPR174MAPK1PKM | |
| SCHEMBL3668675 | 0.79 | CASR (0.66) | CASRNPC1RAB9AMAPK1ALDH1A1 | |
| SCHEMBL20597821 | 0.79 | CASR (0.66) | CASRNPC1RAB9AMAPK1ALDH1A1 | |
| SCHEMBL21611850 | 0.79 | CASR (0.66) | CASRNPC1RAB9AMAPK1ALDH1A1 | |
| SCHEMBL4901299 | 0.77 | CA2 (0.61) | NPC1RAB9AALDH1A1KMT2AEPHX1 | |
| SCHEMBL4113552 | 0.74 | MAPT (0.68) | NPC1RAB9AMAPK1ALDH1A1PKM | |
| SCHEMBL4110299 | 0.74 | RAB9A (0.67) | NPC1RAB9AMAPK1ALDH1A1PKM | |
| SCHEMBL4104760 | 0.74 | MAPT (0.53) | NPC1RAB9AGPR174MAPK1ALDH1A1 | |
| SCHEMBL4897147 | 0.74 | EPHX1 (0.55) | CASRNPC1RAB9AMAPK1ALDH1A1 | |
| SCHEMBL4124258 | 0.74 | MAPT (0.64) | NPC1RAB9AMAPK1ALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009477-A1 | Arylalkyl Ureas As Cb1 Antagonists | NEUROGEN CORPORATION (US) | 2008-01-10 | — | — | US | disclosed |
| US-20080009477-A1 | Arylalkyl Ureas As Cb1 Antagonists | NEUROGEN CORPORATION (US) | 2008-01-10 | — | — | US | disclosed |
| US-20080009477-A1 | Arylalkyl Ureas As Cb1 Antagonists | NEUROGEN CORPORATION (US) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009477-A1 | Arylalkyl Ureas As Cb1 Antagonists | CNR1, CNR2, GPR119 | CASR 1353/4885NPC1 511/4885RAB9A 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.